November 10, 2020

Scientists Discover New Injection Acts Far Better to Prevent Spread of HIV to Women


Trustworthy and indepth news stories are more important now than ever.
Support our newsroom by MAKING A CONTRIBUTION HERE
Women will no longer need to swallow pills daily when the new injection comes on the market

Researchers are stopping a study early after finding that a shot of an experimental medicine every two months worked better than daily pills to help prevent women from contracting HIV from an infected sexual partner.

The news is a boon for AIDS prevention efforts – especially in Africa, where the study took place and where women have few discreet ways of protecting themselves from infection.

Results so far suggest that the drug, cabotegravir, was 89 percent more effective at preventing HIV infection than Truvada pills, although both reduce that risk.

“These results are hugely significant. UNAIDS has long been calling for additional, acceptable and effective HIV prevention options for women, and this could be a real game-changer,” said Winnie Byanyima, Executive Director of UNAIDS. “If donors and countries invest in rolling out access of injectable PrEP to women at higher risk of HIV, new infections could be dramatically reduced.”

The study results are important and timely as more methods to prevent HIV among women at higher risk of HIV are urgently needed, including methods that do not depend on daily or near-daily pill-taking, condom use or abstention from sex.

The development of alternative methods to prevent HIV, and more adherence-friendly schedules than are currently available, will increase the HIV prevention choices and acceptability for women and reduce new HIV infections.

Cabotegravir is being developed by ViiV Healthcare, which is mostly owned by GlaxoSmithKline, with Pfizer Inc and Shionogi Limited.

The study was sponsored by the United States National Institutes of Health (NIH), the Bill and Melinda Gates Foundation and ViiV. The drugs were provided by ViiV and Truvada’s maker, Gilead Sciences.

The trial enrolled over 3200 women aged between 18 and 45 years who were at higher risk of acquiring HIV in Botswana, Kenya, Malawi, South Africa, Eswatini, Uganda and Zimbabwe.

The trial was halted early on the recommendation of the Data and Safety Monitoring Board due to clear statistical evidence showing that the injectable medicine is more effective than a daily pill.

The injection is said to be readily available for global distribution and use in early 2022.

We can't do quality journalism without your support

Perhaps it goes without saying — but producing quality journalism isn't cheap. At a time when newsroom resources and revenue are declining, The Chronicles remains committed to "Serving Your Right To Know The Truth". Stand with us as we document Rwanda's remarkable journey for you and the future generation. Do you value our journalism? We can't do it without you. Show us with your support by CONTRIBUTING HERE.
Email your news TIPS to info@chronicles.rw or WhatsApp +250788351327.
You can also find us on Signal

222 Comments

  1. I may need your help. I tried many ways but couldn’t solve it, but after reading your article, I think you have a way to help me. I’m looking forward for your reply. Thanks.

  2. Excellent beat ! I wish to apprentice while you amend your web site, how can i subscribe for a blog site?

    The account helped me a acceptable deal. I had been a little bit acquainted of this your broadcast offered bright clear concept

  3. What an eye-opening and meticulously-researched article! The author’s meticulousness and aptitude to present complex ideas in a digestible manner is truly praiseworthy. I’m extremely enthralled by the breadth of knowledge showcased in this piece. Thank you, author, for sharing your expertise with us. This article has been a game-changer!

  4. Definitely believe that which you stated. Your favorite reason appeared to be on the internet the easiest thing to be aware of. I say to you, I certainly get annoyed while people think about worries that they just do not know about. You managed to hit the nail upon the top and also defined out the whole thing without having side effect , people can take a signal. Will likely be back to get more. Thanks

Leave a Reply

Your email address will not be published. Required fields are marked *